Skip to main content

Gynaecological Tumours, Breast Cancer

  1. The objective of this study was to investigate the prognostic value of 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake of bone marrow (BM) and metabolic parameters of primary tumor on positron emission tomograp...

    Authors: Jeong Won Lee, Sung Yong Kim, Sun Wook Han, Jong Eun Lee, Hyun Ju Lee, Nam Hun Heo and Sang Mi Lee

    Citation: EJNMMI Research 2020 10:72

    Content type: Original research

    Published on:

  2. Correct identification of tumour receptor status is important for treatment decisions in breast cancer. [18F]FES PET and [18F]FDHT PET allow non-invasive assessment of the oestrogen (ER) and androgen receptor (AR...

    Authors: Lemonitsa H. Mammatas, Clasina M. Venema, Carolina P. Schröder, Henrica C. W. de Vet, Michel van Kruchten, Andor W. J. M. Glaudemans, Maqsood M. Yaqub, Henk M. W. Verheul, Epie Boven, Bert van der Vegt, Erik F. J. de Vries, Elisabeth G. E. de Vries, Otto S. Hoekstra, Geke A. P. Hospers and C. Willemien Menke-van der Houven van Oordt

    Citation: EJNMMI Research 2020 10:40

    Content type: Original research

    Published on:

  3. High expression of human epidermal growth factor receptor type 2 (HER2) represents an aggressive subtype of breast cancer. Anti-HER2 treatment requires a theragnostic approach wherein sufficiently high recepto...

    Authors: Ali Alhuseinalkhudhur, Mark Lubberink, Henrik Lindman, Vladimir Tolmachev, Fredrik Y. Frejd, Joachim Feldwisch, Irina Velikyan and Jens Sörensen

    Citation: EJNMMI Research 2020 10:21

    Content type: Original research

    Published on: